Condition

Clinical trials for Obesity, Abdominal

Active public studies that list Obesity, Abdominal as a condition.

10active studies

5recruiting now

11countries represented

179largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowNot applicable

Circadian Rhythms in Human Adipose

Obesity, Abdominal, Feeding PatternsCondition

Continuous Feeding, Intermittent feedingTreatment

United States1 locations

Mayo ClinicSponsor

Updated 2026-04-14 · NCT06891534See eligibility →

Recruiting nowNot applicable

Nicotinamide Adenine Dinucleotide (NAD+) Metabolism in Human Brown Adipose Tissue

Obesity, AbdominalCondition

NAD+ precursor, PlaceboTreatment

Finland1 locations

University of TurkuSponsor

Updated 2026-02-18 · NCT06627868See eligibility →

Recruiting nowNot applicable

Exploratory Evaluation of the Effect of Cholestyramine on Serum Levels of POPs in Obese Female Patients

Obesity, Abdominal, DiabetesCondition

Cholestyramine PowderTreatment

France1 locations

Centre Hospitalier Universitaire de NiceSponsor

Updated 2025-03-24 · NCT05966727See eligibility →

Recruiting nowNot applicable

Osaka Cardiometabolic Epidemiological Study: Ohtori Study Part 2

Type 2 Diabetes Mellitus (T2DM), Type 2 DiabetesCondition

Intervention not listedTreatment

Japan1 locations

Osaka Metropolitan UniversitySponsor

Updated 2024-12-04 · NCT06694012See eligibility →

Recruiting nowPhase 4

Bioenergetic Effects of Aging and Menopause (BEAM)

Menopause, Obesity, AbdominalCondition

GnRH antagonist, Estrogen ProductTreatment

United States1 locations

University of Colorado, DenverSponsor

Updated 2023-12-18 · NCT04043520See eligibility →

Opening soonPhase 3

A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

Overweight, Prediabetic StateCondition

Orforglipron, PlaceboTreatment

Argentina, China179 locations

Eli Lilly and CompanySponsor

Updated 2026-08-31 · NCT07794579See eligibility →

Opening soonNot applicable

Acupoint Catgut Embedding With Laser Acupuncture for Weight Loss in Adults With Obesity

Obesity, Obesity, AbdominalCondition

Acupoint catgut embedding, Active laser acupunctureTreatment

Taiwan1 locations

Taipei City HospitalSponsor

Updated 2026-08-18 · NCT07770893See eligibility →

Opening soonNot applicable

CPAP in Patients With Severe Obesity After Anesthesia

Obesity, Abdominal, Anesthesia MorbidityCondition

Recruitment/ITP-CPAP (Intervention A), Standard CPAP (Intervention B)Treatment

Locations pending0 locations

Massachusetts General HospitalSponsor

Updated 2025-11-18 · NCT06287632See eligibility →

Invitation onlyNot applicable

Transcriptional Changes in Isolated Human Adipocytes During Obesity

Obesity, Abdominal, AdiposityCondition

Intervention not listedTreatment

Denmark1 locations

University of Southern DenmarkSponsor

Updated 2025-04-02 · NCT06907212See eligibility →

Active, not recruitingNot applicable

EFFECTS OF OLEUROPEIN ON BLOOD PARAMETERS AND INFLAMMATORY MARKERS IN ADULTS WITH METABOLIC SYNDROME

Metabolic Syndrome, Insulin ResistanceCondition

Control Group: Diet Group, Oleuropein and Diet GroupTreatment

Turkey (Türkiye)1 locations

Atlas UniversitySponsor

Updated 2024-11-05 · NCT06673914See eligibility →

Related conditions

Obesity1,102 Obesity & Overweight220 Overweight205 Overweight and Obesity130 Type 2 Diabetes108 Hypertension107

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.